相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single-centre series
Annabel McMillan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results
Ranjana H. Advani et al.
BLOOD (2021)
Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma
Christopher J. Forlenza et al.
BLOOD ADVANCES (2021)
Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma
Ann S. LaCasce et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real-world study
Emilio Iannitto et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2020)
Ifosfamide, gemcitabine, and vinorelbine is an effective salvage regimen with excellent stem cell mobilization in relapsed or refractory pediatric Hodgkin lymphoma
Kristin Marr et al.
PEDIATRIC BLOOD & CANCER (2020)
Comparison of Hodgkin's Lymphoma in Children and Adolescents. A Twenty Year Experience with MH'96 and LH2004 AIEOP (Italian Association of Pediatric Hematology and Oncology) Protocols
Roberta Burnelli et al.
CANCERS (2020)
Response rates, long term outcomes and toxicity profile of gemcitabine and vinorelbine based outpatient chemotherapy regimen in primary progressive and relapsed childhood Hodgkin lymphoma
Mir Rooh Ullah Jan et al.
LEUKEMIA & LYMPHOMA (2020)
Trends in Cancer Incidence in US Adolescents and Young Adults, 1973-2015
Alyssa R. Scott et al.
JAMA NETWORK OPEN (2020)
Risk and Response Adapted Treatment Guidelines for Managing First Relapsed and Refractory Classical Hodgkin Lymphoma in Children and Young People. Recommendations from the EuroNet Pediatric Hodgkin Lymphoma Group
Stephen Daw et al.
HEMASPHERE (2020)
The role of PET/CT in the modern treatment of Hodgkin lymphoma
Jan Maciej Zaucha et al.
CANCER TREATMENT REVIEWS (2019)
Gemcitabine, vinorelbine and dexamethasone: A safe and effective regimen for treatment of relapsed/refractory hodgkin's lymphoma
Prasanth Ganesan et al.
LEUKEMIA RESEARCH (2019)
Alternative salvage regimens for relapsed/refractory classical Hodgkin's lymphoma
Ferenc Magyari et al.
HEMATOLOGY (2016)
The First Step to Integrating Adapted Common Terminology Criteria for Adverse Events for Children
Teresa de Rojas et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study
Pier Luigi Zinzani et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL)
Monica Balzarotti et al.
LEUKEMIA & LYMPHOMA (2016)
Safety and Efficacy of Single-Agent Bendamustine After Failure of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin's Lymphoma: Experience With 27 Patients
Pier Luigi Zinzani et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
Minimizing Late Effects for Patients With Mediastinal Hodgkin Lymphoma: Deep Inspiration Breath-Hold, IMRT, or Both?
Marianne C. Aznar et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2015)
Pediatric Hodgkin Lymphoma
Christine Mauz-Koerholz et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma
Ann S. LaCasce et al.
BLOOD (2015)
Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!
M. A. Kharfan-Dabaja et al.
BONE MARROW TRANSPLANTATION (2014)
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin
Pier Luigi Zinzani et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Phase II Study of Bendamustine in Relapsed and Refractory Hodgkin Lymphoma
Alison J. Moskowitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Evolution of Radiation Therapy Within the German Hodgkin Study Group Trials
Hans Theodor Eich et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2011)
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.
Anas Younes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Phase II Study of Weekly Gemcitabine and Vinorelbine for Children With Recurrent or Refractory Hodgkin's Disease: A Children's Oncology Group Report
Peter D. Cole et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Survival from cancer in teenagers and young adults in England, 1979-2003
J. M. Birch et al.
BRITISH JOURNAL OF CANCER (2008)
分享论文
